Review Article
Prognostic Value of MTV and TLG of 18F-FDG PET in Patients with Stage I and II Non-Small-Cell Lung Cancer: a Meta-Analysis
Table 1
Features of included studies.
| Study | Year | Country | Study period | Follow-up duration (months) | Median age (range), years | No. of patients | TNM staging | End points | Study design | Histology | Treatment |
| Suman et al. | 2020 | Japan | 2010.6–2016.10 | 44.8 | 73 (53–85) | 39 | I | OS PFS | Retro | Adenocarcinoma Squamous cell carcinoma | Radiotherapy | Domachevsky et al. | 2015 | Israel | 2007–2012 | 60 | 68.7 ± 8.9 | 181 | I-II | OS | Retro | Adenocarcinoma Squamous cell carcinoma Mixed/sarcomatoid Bronchioloalveolar Adenocarcinoma with bronchioloalveolar | Surgery | Seong et al. | 2015 | Korea | 2006.2–2011.12 | 36.6 | 63.03 ± 10.01 | 248 | I | OS | Retro | Adenocarcinoma Nonadenocarcinoma | Surgery | Seung et al. | 2013 | Korea | 2003.7–2006.12 | 60 | 63 (23–83) | 529 | I-II | OS DFS | Retro | Adenocarcinoma Squamous cell carcinoma Large cell carcinoma Adenosquamous carcinoma Others | Surgery Chemotherapy Radiotherapy | Charles et al. | 2013 | USA | 2007.5–2012.12 | 25.1 | 73.3 | 50 | I | OS RFS | Retro | Adenocarcinoma Squamous cell carcinoma Others | Radiotherapy | Melloni et al. | 2013 | Italy | 2005.1–2011.1 | 21 (3–68) | 68(40–85) | 99 | I | PFS | Retro | Adenocarcinoma Others | Surgery | Abelson et al. | 2012 | USA | 2005.9–2009.12 | 13.2 | 80.1(57.6–93.4) | 84 | I | OS | Retro | Squamous cell carcinoma Adenocarcinoma Non-small-cell Atypia | Radiotherapy | Lin Y et al. | 2012 | Taiwan | 2009.1–2011.2 | 24(8–36) | 63(38–85) | 62 | I | PFS | Retro | Squamous cell carcinoma Adenocarcinoma | Surgery |
|
|
Abbreviations: Retro = retrospective; PFS = progression-free survival; DFS = disease-free survival; RFS = recurrence-free survival; OS = overall survival.
|